目的 探讨依达拉奉联合低分子肝素钙治疗急性进展性脑梗死的疗效及安全性.方法 将急性进展性脑梗死患者72例随机分为治疗组(36例)和对照组(36例).两组基础治疗相同,治疗组采用依达拉奉30 mg加入生理盐水100 mL,静脉滴注,2次/d,共14 d,低分子肝素钙注射液0.4 mL,脐周皮下注射,1次/12 h,共7 d;对照组应用常规综合治疗.两组于治疗前及治疗14 d后分别进行神经功能缺损评分(NIHSS)及临床疗效比较.结果 两组治疗后神经功能缺损评分均有下降(P ＜ 0.05),且治疗组与对照组相比,差异有统计学意义(P ＜ 0.05);同时治疗组治疗后基本痊愈率和总有效率均显著高于对照组,差异有统计学意义(P ＜ 0.05).结论 依达拉奉联合低分子肝素钙治疗进展性脑梗死疗效显著,安全可靠.%Objective To explore the clinical effect of Edaravone combined with Low Molecular Weight Heparin in therntreatment of progressive cerebral infarction. Methods 72 cases of patients with progressive cerebral infarction in ourrnhospital were divided into observation group (36 cases) and control group (36 cases). All patients received conventionalrntreatment, based on which, the observation group was treated with Edaravone 30 mg+NS 100 mL ivgtt, bid, for 14 d,rncombined with Low Molecular Weight Heparin 0.4 mL, sc, ql2h, for 7 d. The clinical effect and the neurologicalrndeficit scale scores (NIHSS) before and after treatment for 14 days of two groups were compared and analyzed. ResultsrnCompared with before treatment, NIHSS in both groups were decreased evidently (P < 0.05), and the difference of therntwo groups was significant (P < 0.05). The patients in observation group had a higher basic recovery rate, total effectivernrate, the differences of which between the two groups were significant (P < 0.05). Conclusion Edaravone combinedrnwith Low Molecular Weight Heparin to treat heparin progressive cerebral infarction is clinically significantly effectivernand safe.
展开▼
